Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans

By Kanazu T.   Yamaguchi Y.   Okamura N.   Baba T.   Koike M.  

Xenobiotica, Vol. 34, Iss. 5, 2004-05 ,pp. : 391-402

Informa Healthcare

Access to resources Recommend Favorite

Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug–drug interaction model rats

By Kanazu Takushi   Okamura Noboru   Yamaguchi Yoshitaka   Baba Takahiko   Koike Masahiro  

Xenobiotica, Vol. 35, Iss. 4, 2005-04 ,pp. : 305-317

Informa Healthcare

Access to resources Recommend Favorite

CYP Inhibition-Mediated Drug-Drug Interactions

By  

Current Enzyme Inhibition, Vol. 6, Iss. 3, 2010-10 ,pp. : 130-145

Bentham Science Publishers

Access to resources Recommend Favorite

Enzymatic characteristics of CYP3A5 and CYP3A4: A comparison of in vitro kinetic and drug–drug interaction patterns

By Emoto C.   Iwasaki K.  

Xenobiotica, Vol. 36, Iss. 2-3, 2006-02 ,pp. : 219-233

Informa Healthcare

Access to resources Recommend Favorite

Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

By Tachibana T.   Kato M.   Watanabe T.   Mitsui T.   Sugiyama Y.  

Xenobiotica, Vol. 39, Iss. 6, 2009-06 ,pp. : 430-443

Informa Healthcare

Access to resources Recommend Favorite